Close
FINDING CURES TOGETHER<sup>SM</sup>

Advances in Ovarian Cancer Research

​Program 

Friday, Sept. 13, 2019

Saturday, Sept. 14, 2019

Sunday, Sept. 15, 2019

Monday, Sept. 16, 2019


Friday, Sept. 13, 2019

Opening Keynote Session
Welcome Remarks and Session Chair: Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts
6-7:30 p.m.

T-cell response in ovarian cancer
George Coukos, Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland


Welcome Reception
7:30-9:30 p.m.


Saturday, Sept. 14, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 1: Drug Resistance and Acquired Vulnerabilities
Session Chair: Clare L. Scott, Walter & Eliza Hall Institute of Medicine Research, Parkville, VIC, Australia
8-10 a.m.

DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response
Clare L. Scott

PARP inhibitor and platinum resistance in ovarian cancer genome-wide CRISPR screens
Dipanjan Chowdhury, Dana-Farber Cancer Institute, Boston, Massachusetts

Drug resistance in end-stage high grade serous ovarian cancer
Elizabeth Christie, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Assessment of PARPi and cisplatin resistance in BRCA1 exon 11 mutant patient-derived xenografts*
John Krais, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Proteogenomic approach to identify mechanisms of platinum refractoriness in high-grade serous ovarian cancers*
Amanda Paulovich, Fred Hutchinson Cancer Research Center, Seattle, Washington


Break
10-10:30 a.m.


Plenary Session 2: Exceptional Responders
Session Chair: David D.L. Bowtell, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
10:30 a.m.-12:30 p.m.

Molecular analysis of exceptional response in high-grade serous ovarian cancer
David D.L. Bowtell

The Long-Term Ovarian Cancer Survivor Project: A Department of Defense initiative 
Michael J. Birrer, University of Alabama Comprehensive Cancer Center, Birmingham, Alabama

The role of lifestyle and immune factors on long-term survival with ovarian cancer
Celeste “Leigh” Pearce, University of Michigan School of Public Health, Ann Arbor, Michigan

Understanding disease biology by investigating exceptional responders
Stéphanie Lheureux, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

Single-cell proteomic analysis of the tumoral heterogeneity in response to PARP inhibitor*
Marilyne Labrie, Oregon Health & Science University, Portland, Oregon


Free Time (Lunch on Own)
12:30-3 p.m.


Plenary Session 3: Risk, Prevention, and Early Detection
Session Chair: Karen H. Lu, The University of Texas MD Anderson Cancer Center, Houston, Texas
3-5 p.m.

Challenges in the identification of inherited risk of ovarian cancer
Barbara Norquist, University of Washington, Seattle, Washington

Traditional and modern approaches for prevention and early detection
Douglas A. Levine, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York

Women at high risk for ovarian cancer: Novel strategies for identification and prevention
Karen H. Lu

The Ovarian Tumour Tissue Analysis Consortium: Stratified Prognosis of Ovarian Tumors (OTTA-SPOT) signature for high-grade serous ovarian cancer
Susan J. Ramus, University of New South Wales, Sydney, Australia

Analyses of Pax2 and Pax8 in maintaining oviduct epithelial homeostasis and fertility*
Abdulsalam Soofi, University of Michigan, Ann Arbor, Michigan


Poster Session A / Reception
5-7:30 p.m.


Top of page


Sunday, Sept. 15, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 4: Organoids and Model Systems
Session Chair: Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts
8-10 a.m.

Organoids and model systems: Rare ovarian cancers
David G. Huntsman, University of British Columbia, Vancouver, BC, Canada

Integrated molecular characterization of the genome, transcriptome, and immune microenvironment in oviductal high-grade serous carcinomas arising in genetically engineered mice
Kathleen R. Cho, University of Michigan Medical School, Ann Arbor, Michigan

Modeling the tumor microenviroment of high-grade serous ovarian cancer
Frances R. Balkwill, Barts Cancer Institute, London, United Kingdom

Patient-derived tumoroids for exploration of the ovarian cancer stem cell regulation, chemoresistance, and tumor heterogeneity*
Geeta Mehta, University of Michigan, Ann Arbor, Michigan

Dissecting mechanisms of replication fork stabilization in patient-derived high-grade serous organoid cultures and their impact on therapeutic sensitivity and the immune-tumor interaction*
Sarah Hill, Dana-Farber Cancer Institute, Boston, Massachusetts


Break
10-10:30 a.m.


Plenary Session 5: Tumor Microenvironment
Session Chair: Juan R. Cubillos-Ruiz, Weill Cornell Medical College, New York, New York
10:30 a.m.-12:30 p.m.

ER stress responses shape the ovarian cancer immune microenvironment
Juan R. Cubillos-Ruiz

PARP inhibition modulates the tumor immune microenvironment in Brca1-deficient ovarian tumor
Jean J. Zhao, Dana-Farber Cancer Institute, Boston, Massachusetts

Metabolic impact on cancer immunity
Weiping Zou, University of Michigan, Ann Arbor, Michigan

Reprogramming the tumor microenvironment with losartan to enhance immunotherapy of ovarian cancer*
Lei Xu, Massachusetts General Hospital, Boston, Massachusetts

High-grade serous ovarian tumor cells modulate natural killer cells to create an immune-tolerant microenvironment*
Wendy Fantl, Stanford University, Stanford, California


Poster Session B / Lunch
12:30-3:30 p.m.


Plenary Session 6: Immunotherapy
Session Chair: George Coukos, Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland
3:30-5:30 p.m.

Immunotherapy in ovarian cancer: Challenges and novel opportunities
Dmitriy Zamarin, Memorial Sloan Kettering Cancer Center, New York, New York

Personalized whole-tumor antigen vaccines in ovarian cancer: Using tumors for therapy
Lana E. Kandalaft, Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland

MUC16-directed immunotherapy for ovarian cancer
Oladapo O. Yeku, Massachusetts General Hospital, Boston, Massachusetts

An unexpectedly effective immunotherapy strategy for ovarian cancer*
Jogender Tushir-Singh, University of Virginia, Charlottesville, Virginia

High-throughput functional and multi-omic single-cell characterization to elucidate ovarian intratumor and microenvironmental heterogeneity*
Kristin Beaumont, Icahn School of Medicine at Mount Sinai, New York, New York


Evening on Own
5:30 p.m.-


Monday, Sept. 16, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 7: Rare Tumors
Session Chair: David M. Gershenson, The University of Texas MD Anderson Cancer Center, Houston, Texas
8-10 a.m.

Therapeutic approaches for ARID1A-mutated ovarian cancer
Rugang Zhang, University of Pennsylvania, Philadelphia, Pennsylvania

Low-grade serous ovarian cancer: Recent advances and future directions
Rachel N. Grisham, Memorial Sloan Kettering Cancer Center, New York, New York

Personalizing treatment for women with rare epithelial ovarian cancers (EOC): Lessons learned
David M. Gershenson

Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear-cell ovarian cancers*
Yasuto Kinose, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania


Break
10-10:15 a.m.


Plenary Session 8: Bench to Bedside – Gaps / Needs Panel Discussion
Session Chair: Karen H. Lu, The University of Texas MD Anderson Cancer Center, Houston, Texas
10:15-11:30 a.m.

Genetic aberrations dictate distinct tumor immune landscape and chemosensitivity in HGSOC*
Shuang Zhang, NYU Langone Laura and Isaac Perlmutter Cancer Center, New York, New York

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer*
Elaine Sanij, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Combined PARP and immune checkpoint inhibition in ovarian cancer
Panagiotis A. Konstantinopoulos, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts


Closing Remarks and Departure
11:30 a.m.


*Short talk from proffered abstract


Top of page